<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02757404</url>
  </required_header>
  <id_info>
    <org_study_id>MT_PRT_ST04</org_study_id>
    <nct_id>NCT02757404</nct_id>
  </id_info>
  <brief_title>Meditoxin® Treatment in Patients With Post Stroke Upper Limb Spasticity</brief_title>
  <official_title>Impact of Injection Techniques on the Effectiveness of Botulinum Toxin for the Treatment of Post Stroke Upper Limb Spasticity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medy-Tox</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medy-Tox</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Botulinum Toxin for the Treatment of Post Stroke Upper Limb Spasticity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is &quot;A Multicenter, Prospective, Randomized, Evaluator Blinded, Comparing Phase 4
      Study to Evaluate the Impact of Injection Techniques on the Effectiveness of Botulinum Toxin
      for the Treatment of Post Stroke Upper Limb Spasticity&quot;.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 30, 2016</start_date>
  <completion_date type="Actual">August 16, 2016</completion_date>
  <primary_completion_date type="Actual">August 16, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison evaluation on improvement rate of spasticity assessed by Modified Ashworth Scale between 3 arms.</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison evaluation on improvement rate of spasticity assessed by Modified Tardieu Scale between 3 arms.</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison evaluation on improvement rate of range of motion on each joint between 3 arms.</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Muscle Spasticity</condition>
  <arm_group>
    <arm_group_label>Ultrasonography guidance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ultrasonography guidance injection of Meditoxin®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Electrical stimulation guidance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Electrical stimulation guidance injection of Meditoxin®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Manual needle placement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Manual needle placement injection of Meditoxin®.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ultrasonography guidance injection of Meditoxin®.</intervention_name>
    <description>Meditoxin® will be injected to upper limb spasticity by using the ultrasonography guidance.</description>
    <arm_group_label>Ultrasonography guidance</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Electrical stimulation guidance injection of Meditoxin®.</intervention_name>
    <description>Meditoxin® will be injected to upper limb spasticity by using the electrical stimulation guidance.</description>
    <arm_group_label>Electrical stimulation guidance</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Manual needle placement injection of Meditoxin®.</intervention_name>
    <description>Meditoxin® will be injected to upper limb spasticity by using the manual needle placement.</description>
    <arm_group_label>Manual needle placement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subject aged over 20.

          2. Subjects who has grade 1 + and more spasticity at least one of upper limb muscles as
             measured on Modified Ashworth Scale after stroke.

          3. Subjects who was diagnosed stroke at least 1 month prior to study participation.

          4. Subjects or legal representatives who voluntarily decided the participation of the
             study and signed the informed consent.

        Exclusion Criteria:

          1. Subjects who had spinal injuries to be a factor of spasticity except for stroke prior
             to study enrollment.

          2. Subjects with allergy or hypersensitivity to the Botulinum Toxin.

          3. Subjects who have changed the muscle relaxant taking for treatment within past 4 weeks
             prior to study participation.

          4. Subjects who have taken injection treatments using alcohol or phenol in upper limb
             within past 6 months prior to study participation.

          5. Subjects with general neuromuscular synaptic disorder(e.g. Myasthenia gravis,
             Lambert-Eaton syndrome, Amyotrophic lateral sclerosis).

          6. Subjects who have been injected with botulinum toxin within past 3 months before the
             injection.

          7. Subjects who are pregnant or lactating of disagreed to avoid pregnancy during 3 months
             study period.

          8. Subjects who are scheduled to take part in other clinical trial during the study
             period.

          9. Patients who are not eligible for this study at the medical discretion of the
             investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MyungEun Chung</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Paul's Hospital, The Catholic University of Korea</affiliation>
  </overall_official>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>April 25, 2016</study_first_submitted>
  <study_first_submitted_qc>April 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2016</study_first_posted>
  <last_update_submitted>March 27, 2019</last_update_submitted>
  <last_update_submitted_qc>March 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>botulinum toxin</keyword>
  <keyword>spasticity</keyword>
  <keyword>injection technique</keyword>
  <keyword>neuronox</keyword>
  <keyword>meditoxin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Spasticity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

